Prospective studies, including standardized clinical assessments with longitudinal measurement of established and emergent clinical features and biomarkers (eg, neurofilament light chain,33,34 phosphorylated tau35,36), are needed to further inform the care of patients with CJD. The gene discussed is NEFL; the disease is Creutzfeldt Jacob disease.